Search Results for "daptomycin"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for daptomycin. Results 11 to 13 of 13 total matches.
See also: Cubicin
Two New Drugs for Skin and Skin Structure Infections
The Medical Letter on Drugs and Therapeutics • Aug 18, 2014 (Issue 1449)
are usually treated with IV vancomycin.
Alternatives include linezolid, daptomycin,
clindamycin, telavancin ...
The FDA has approved two new drugs for treatment
of adults with acute bacterial skin and skin structure
infections caused by susceptible gram-positive
bacteria. Dalbavancin (Dalvance – Durata) is a long-acting
intravenous (IV) lipoglycopeptide antibiotic
similar to telavancin (Vibativ). Tedizolid phosphate
(Sivextro – Cubist) is an IV and oral oxazolidinone
antibacterial drug similar to linezolid (Zyvox). A
third IV antibiotic, oritavancin (Orbactiv), recently
approved by the FDA for the same indication, will be
reviewed in a future...
Drugs for Bacterial Infections
Treatment Guidelines from The Medical Letter • Jul 01, 2013 (Issue 131)
or daptomycin.
For complicated polymicrobial infections
that could include MRSA, one of these drugs could ...
The text that follows reviews some common bacterial
infections and their empiric treatment pending the
results of culture and susceptibility testing. The recommendations
made here are based on the results of
susceptibility studies, clinical trials, and the opinions
of Medical Letter reviewers. Tables 1 and 2 list the usual
dosages of antibacterial drugs.
Oritavancin (Orbactiv) for Skin and Skin Structure Infections
The Medical Letter on Drugs and Therapeutics • Jan 05, 2015 (Issue 1459)
Cubicin dalbavancin Dalvance Daptomycin clindamycin ceftriaxone ceftaroline cefazolin antibacterials skin ...
The FDA has approved oritavancin (Orbactiv – The
Medicines Company), a long-acting lipoglycopeptide
antibiotic given as a single intravenous (IV) dose, for
treatment of acute bacterial skin and skin structure
infections caused by susceptible gram-positive
bacteria in adults. It is the third lipoglycopeptide
antibiotic to be marketed in the US; telavancin (Vibativ)
and dalbavancin (Dalvance) were approved earlier.